

# Non-Hodgkin's Lymphoma Clinical Trial Pipeline | 200+ Companies Driving Innovation to Transform Treatment

*Major pharma companies are working to advance the pipeline space and unlock the future growth potential of the Non-Hodgkin's Lymphoma treatment landscape.*

LAS VEGAS , NV, UNITED STATES, February 7, 2025 /EINPresswire.com/ -- DelveInsight's 'Non-Hodgkin's Lymphoma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Non-Hodgkin's Lymphoma therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Non-Hodgkin's Lymphoma pipeline domain.

For Non-Hodgkin's Lymphoma emerging drugs, the Non-Hodgkin's Lymphoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

## Key Takeaways from the Non-Hodgkin's Lymphoma Pipeline Report

- DelveInsight's Non-Hodgkin's Lymphoma Pipeline analysis depicts a robust space with 200+ active players working to develop 220+ pipeline drugs for Non-Hodgkin's Lymphoma treatment.
- The leading Non-Hodgkin's Lymphoma companies include Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Tenebio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others are evaluating their lead assets to improve the Non-Hodgkin's Lymphoma treatment landscape.
- Key Non-Hodgkin's Lymphoma pipeline therapies in various stages of development include Mosunetuzumab, Tisagenlecleucel, Capivasertib, Azeliragon, BI-1206, HMPL-760, ABBV-291, GNC-038, CNCT19, MBS303, GNC-035, Glofitamab, Obinutuzumab, HMPL-760, EB103, ME-401, CG-806, ME-401, ABBV-525, ABT-263, Venetoclax, and others.

- In August 2024, the FDA cleared Galapagos' IND application to begin the Phase I/II ATALANTA-1 study of GLPG5101 for relapsed/refractory non-Hodgkin lymphoma (r/r NHL), evaluating its feasibility, safety, and efficacy.
- In May 2024, Bristol Myers Squibb announced that the FDA approved Breyanzi® (lisocabtagene maraleucel), a CD19-directed CAR T cell therapy, for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two prior treatments, including a BTK inhibitor. This approval makes Breyanzi the CAR T therapy for the broadest range of B-cell malignancies.

Request a sample and discover the recent breakthroughs happening in the Non-Hodgkin's Lymphoma pipeline landscape @ Non-Hodgkin's Lymphoma Pipeline Outlook

### Non-Hodgkin's Lymphoma Overview

Non-Hodgkin Lymphoma (NHL) is a group of cancers affecting the lymphatic system, primarily originating in the lymph nodes. With over 86 subtypes classified by the WHO, NHL varies in molecular characteristics, growth patterns, and treatment responses. It is the seventh most common cancer in U.S. adults, with incidence nearly doubling from 1975 to 2013. Symptoms include painless lymph node swelling, fever, night sweats, weight loss, and fatigue. While these signs can indicate other conditions, persistent or severe symptoms should prompt medical evaluation.

NHL arises from genetic abnormalities in B cells, T cells, or natural killer cells, often due to chromosomal translocations or mutations. The t(14; 18) translocation is common in follicular lymphoma, while t(11; 14) is linked to mantle cell lymphoma. Burkitt lymphoma is associated with the t(8; 14) translocation, and BCL-2/BCL-6 alterations are seen in diffuse large B-cell lymphoma. Primary CNS lymphoma is frequently linked to HIV/AIDS.

Treatment depends on the subtype, stage, and disease characteristics. Standard options include chemotherapy, radiation, immunotherapy, and stem cell transplants. Chemoimmunotherapy, particularly rituximab with chemotherapy, is widely used for B-cell lymphomas. Early-stage disease (I and II) is often treated with radiation, while advanced stages (II bulky, III, IV) require combined therapies. Advances in targeted treatments continue to improve NHL outcomes.

Find out more about Non-Hodgkin's Lymphoma medication @

[https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=jpr](https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=jpr)

### Non-Hodgkin's Lymphoma Treatment Analysis: Drug Profile

#### Mosunetuzumab: Hoffmann-la Roche

Mosunetuzumab is an investigational, humanized T-cell bispecific antibody designed to activate T cells and direct their cytotoxic activity against malignant B cells. It binds simultaneously to CD3 epsilon (CD3e), a key T-cell receptor (TCR) complex component, and CD20, a surface protein found on most B-cell malignancies. This crosslinking triggers TCR signaling, leading to targeted B-

cell destruction. Structural features of mosunetuzumab enhance T-cell recruitment and retention, amplifying its antitumor effect.

Preclinical studies have shown that mosunetuzumab induces T-cell proliferation and effectively eliminates B cells, even at low effector-to-target (T cell:B cell) ratios. Combined with PD-L1 inhibition, it may help overcome adaptive immune resistance, further enhancing anticancer activity against B-cell malignancies. Currently, mosunetuzumab is being evaluated in a Phase III trial assessing its efficacy and safety in combination with polatuzumab vedotin, compared to rituximab with gemcitabine and oxaliplatin, in patients with relapsed or refractory aggressive B-cell Non-Hodgkin's Lymphoma.

Tisagenlecleucel: Novartis

Tisagenlecleucel is a CD19-directed autologous T-cell immunotherapy designed to target and eliminate malignant B cells. It involves genetically modifying a patient's own T cells using a lentiviral vector to encode an anti-CD19 chimeric antigen receptor (CAR). The CAR consists of a murine single-chain antibody fragment (scFv) specific to CD19, a CD8 hinge and transmembrane region, and intracellular signaling domains from 4-1BB (CD137) and CD3 zeta.

These signaling domains enhance CAR T-cell expansion, persistence, and potency. The CD3 zeta domain is crucial for initiating T-cell activation and antitumor activity, while 4-1BB supports prolonged T-cell survival and function. Upon binding to CD19-expressing cells, tisagenlecleucel triggers T-cell expansion, activation, and tumor cell elimination.

Currently, tisagenlecleucel is in Phase III clinical trials for the treatment of Non-Hodgkin Lymphoma, evaluating its efficacy and safety in patients with relapsed or refractory disease.

Key Non-Hodgkin's Lymphoma Therapies and Companies

- Mosunetuzumab: Hoffmann-la Roche
- Tisagenlecleucel: Novartis
- Capivasertib: AstraZeneca
- Azeliragon: Cantex
- BI-1206: BioInvent
- HMPL-760: Hutchmed
- ABBV-291: AbbVie
- GNC-038: Sichuan Baili Pharmaceutical Co., Ltd.
- CNCT19: Juventas Cell Therapy Ltd.
- MBS303: Beijing Mabworks Biotech Co., Ltd.
- GNC-035: Sichuan Baili Pharmaceutical Co., Ltd.
- Glofitamab: Hoffmann-La Roche
- Obinutuzumab: Hoffmann-La Roche
- HMPL-760: Hutchison Medipharma Limited
- EB103: Estrella Biopharma, Inc.
- ME-401: Kyowa Kirin Co., Ltd.

- CG-806: Aptose Biosciences Inc.
- ME-401: Kyowa Kirin Co., Ltd.
- ABBV-525: AbbVie
- ABT-263: AbbVie
- Venetoclax: AbbVie

Learn more about the novel and emerging Non-Hodgkin's Lymphoma pipeline therapies @ [https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=jpr](https://www.delveinsight.com/report-store/non-hodgkins-lymphoma-nhl-pipeline-insight?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=jpr)

## Non-Hodgkin's Lymphoma Therapeutics Assessment

### By Product Type

- Mono
- Combination
- Mono/Combination.

### By Stage

- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

### By Route of Administration

- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical

### By Molecule Type

- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy

### Scope of the Non-Hodgkin's Lymphoma Pipeline Report

- Coverage: Global
- Key Non-Hodgkin's Lymphoma Companies: Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences, Ltd., Timmune Biotech Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Gilead Sciences, Acerta Pharma BV, Adagene Inc, Conjupro Biotherapeutics, Inc., Rhizen

Pharmaceuticals, Juventas Cell Therapy Ltd., Incyte Corporation, HUYA Bioscience International, SecuraBio, Genor Biopharma Co., Ltd., Kyowa Kirin Co., Ltd., Antengene Therapeutics Limited, Regeneron Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., Xynomic Pharmaceuticals, Inc., BioTheryX, Inc., UWELL Biopharma, Kronos Bio, Bio-Thera Solutions, Spectrum Pharmaceuticals, Inc., Aptose Biosciences Inc., Miltenyi Biomedicine GmbH, Precision BioSciences, Inc., Teneobio, Inc., TCR2 Therapeutics, IGM Biosciences, Inc., and others.

• Key Non-Hodgkin's Lymphoma Pipeline Therapies: Mosunetuzumab, Tisagenlecleucel, Capivasertib, Azeliragon, BI-1206, HMPL-760, ABBV-291, GNC-038, CNCT19, MBS303, GNC-035, Glofitamab, Obinutuzumab, HMPL-760, EB103, ME-401, CG-806, ME-401, ABBV-525, ABT-263, Venetoclax, and others.

Dive deep into rich insights for drugs used for Non-Hodgkin's Lymphoma treatment; visit @ Non-Hodgkin's Lymphoma Drugs

## Table of Contents

1. Introduction
2. Executive Summary
3. Non-Hodgkin's Lymphoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Non-Hodgkin's Lymphoma Pipeline Therapeutics
6. Non-Hodgkin's Lymphoma Pipeline: Late-Stage Products (Phase III)
7. Non-Hodgkin's Lymphoma Pipeline: Late-Stage Products (Phase III)
8. Non-Hodgkin's Lymphoma Pipeline: Mid-Stage Products (Phase II)
9. Non-Hodgkin's Lymphoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

## Related Reports

Hepatitis C Virus Infection Pipeline: <https://www.delveinsight.com/report-store/hepatitis-c-virus-infection-pipeline-insight>

Hepatitis C Market: <https://www.delveinsight.com/report-store/hepatitis-c-market>

Helicobacter Pylori Infection Pipeline: <https://www.delveinsight.com/report-store/helicobacter->

[pylori-infections-pipeline-insight](#)

Epstein Barr virus Market: <https://www.delveinsight.com/report-store/epstein-barr-virus-ebv-market>

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Jatin Vimal

DelveInsight Business Research LLP

+1 469-945-7679

info@delveinsight.com

---

This press release can be viewed online at: <https://www.einpresswire.com/article/784012767>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.